Glemont-A Tablet SR is a combination medication containing Acebrophylline 200 mg and Montelukast 10 mg, formulated to provide sustained relief in the management of respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and bronchitis. Acebrophylline acts as a bronchodilator and mucolytic agent, facilitating the relaxation of airway smooth muscles and promoting the clearance of mucus, thereby improving airflow and reducing bronchial congestion. Montelukast, a leukotriene receptor antagonist, inhibits the action of leukotrienes involved in the inflammatory process, effectively reducing airway inflammation, bronchoconstriction, and hyperresponsiveness. The sustained-release formulation ensures prolonged therapeutic effects, enhancing patient compliance by reducing dosing frequency. Glemont-A Tablet SR is indicated for patients requiring combined bronchodilator and anti-inflammatory therapy to control symptoms such as wheezing, shortness of breath, and coughing associated with obstructive airway diseases. It should be used under medical supervision, with consideration of patient history and potential drug interactions. Common side effects may include headache, gastrointestinal disturbances, and mild allergic reactions. Regular monitoring and adherence to prescribed dosage are essential to optimize treatment outcomes and minimize adverse effects.